Raynaud's phenomenon

Joint Bone Spine

Volumn 74, Issue 1, 2007, Pages e1-

  Gayraud, Martine ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Calcium channel antagonists; Raynaud's phenomenon; Scleroderma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; BOSENTAN; BUFLOMEDIL; CYCLOSPORIN A; DIHYDROERGOCRYPTINE; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ERGOT DERIVATIVE; FIBRINOLYTIC AGENT; FLUOXETINE; GLYCERYL TRINITRATE; ILOPROST; LOSARTAN; NAFTIDROFURYL; NIFEDIPINE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROSTAGLANDIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL;

ACUPUNCTURE; AORTA ARCH SYNDROME; ATHEROMA; BUERGER DISEASE; CANCER; CARCINOID SYNDROME; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EMBOLISM; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; HOT FLUSH; HUMAN; HYPOTHYROIDISM; INJURY; LOW LEVEL LASER THERAPY; LYMPHOPROLIFERATIVE DISEASE; MIXED CONNECTIVE TISSUE DISEASE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PHEOCHROMOCYTOMA; RAYNAUD PHENOMENON; REPETITIVE STRAIN INJURY; SHORT SURVEY; SJOEGREN SYNDROME; SYMPATHETIC BLOCKING; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THERAPY EFFECT; THORAX OUTLET SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33846910264     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.07.002     Document Type: Short Survey

References (55)

1. Carpentier P.H. Définition et épidémiologie des acrosyndromes vasculaires. Rev Prat 46 (1998) 1641-1646
2. Block J.A., and Sequeira W. Raynaud's phenomenon. Lancet 357 (2001) 2042-2048
3. Wigley F.M. Raynaud's phenomenon. N Engl J Med 347 (2002) 1001-1008
4. O'Keefe S.T., Tsapatsaris N.P., and Beetham W.P. Increased prevalence of migraine and chest pain in patients with primary Raynaud's disease. Ann Intern Med 116 (1992) 985-989
5. Suter L.G., Murabito J.M., Felson D.T., and Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 52 (2005) 1259-1263
6. Olsen N., and Nielsen S.L. Prevalence of primary Raynaud phenomena in young females. Scand J Clin Lab Invest 37 (1978) 761-764
7. Jones G.T., Herrick A.L., Woodham S.E., Baildam E., Macfarlane G.I., and Silman A.J. Occurrence of Raynaud's phenomenon in children aged 12-15 years. Arthritis Rheum 48 (2003) 3518-3523
8. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology 44 (2005) 587-596
9. Flavahan N.A., Flavahan S., Mitra S., and Chotani M.A. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 29 (2003) 275-291
10. Mayes M.D. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48 (2003) 1190-1199
11. Furspan P.B., Chatterjee S., Mayes M.D., and Freedman R.R. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology 44 (2005) 488-494
12. Furspan P.B., Chatterjee S., and Freedman R.R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 50 (2004) 1578-1585
13. Generini S., Seibold J.R., and Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 31 (2005) 177-186
14. Planchon B., Pistorius M.A., Beurrier P., and de Faucal P. Primary's Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 45 (1994) 677-686
15. Ziegler S., Brunner M., Eigenbauer E., and Minar E. Long-term outcome of primary's Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol 32 (2003) 343-347
16. Manmarino E., Pasqualini L., Fedeli F., Scricciolo V., and Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon. Angiology 45 (1994) 37-42
17. Cutolo M., Grassi W., and Matucci-Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48 (2003) 3023-3030
18. Hatron P.Y., Frimat P., and Hachulla E. Phénomènes de Raynaud d'origine professionnelle. Rev Prat 48 (1998) 1653-1658
19. Boillat M.A., and Thorens B. Acrosyndromes et maladies professionnelles: épidémiologie et prévention de la maladie des engins vibrants. Rev Med Suisse Romande 112 (1992) 405-407
20. Hachulla E., Gillard J., and Duquesnoy B. Clinique du syndrome de la traversée cervico-thoraco-brachiale. Rev Med Int 5 Suppl (1999) 464-467
21. Belch J.J., and Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 52 (1996) 682-695
22. Allanore Y., and Kahan A. Treatment of systemic sclerosis. Joint Bone Spine 73 (2006) 363-368
23. Allanore Y., Borderie D., Lemarechal H., Ekindjian O.G., and Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 116 (2004) 595-600
24. Thompson A.E., and Pope J.E. Calcium channel blockers for primary's Raynaud's phenomenon: a metaanalysis. Rheumatology 44 (2005) 145-150
25. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 160 (2000) 1101-1108
26. Thompson A.E., Shea B., Welch V., Fenlon D., and Pope J.E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44 (2001) 1841-1847
27. Hummers L.K., and Wigley F.M. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29 (2003) 293-313
28. The L.S., Manning J., Moore T., Tully M.P., O'Reilly D., and Jayson M.I.V. Sustained-release transdermal glyceryl trinitrate patches as treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 34 (1995) 636-641
29. Wise R.A., Wigley F.M., White B., Leatherman G., Zhong J., Krasa H., et al. Efficacy and tolerability of a selective α2c-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. Arthritis Rheum 50 (2004) 3994-4001
30. Le Quintrec P., and Lefebvre M.L. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up. Angiology 42 (1991) 289-295
31. Davinroy M., and Mosnier M. Evaluation clinique en double-insu du naftidrofuryl dans le phénomène de Raynaud. Sem Hop Paris 69 (1993) 1322-1326
32. Wigley F.M., Wise R.A., Seibold J.R., McCloskey D.A., Kujala G., Medsger Jr. T.A., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med 120 (1994) 199-206
33. Torlay H.I., Madock R., Capell H.A., Brouwer R.M., Maddison P.J., Black C.M., et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50 (1991) 800-804
34. Scorza R., Caronni M., Mascagni B., Berruti V., Bazzi S., Micaleff E., et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study. Clin Exp Rheumatol 19 (2001) 503-508
35. Rademaker M., Cooke E.D., Almond N.E., Beacham J.A., Smith R.E., Mant T.G., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298 (1989) 561-564
36. Wigley F.M., Korn J.H., Czuka M.E., Medsger T.A., Rothfield N.F., Ellman M., et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Arthritis Rheum 41 (1998) 670-677
37. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26 (1999) 2173-2178
38. Humbert M., Sitbon O., and Simonneau G. Drug therapy: treatment of pulmonary hypertension. N Engl J Med 351 (2004) 1425-1436
39. Braun-Moscovici Y., Nahir A.M., and Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 34 (2004) 442-453
40. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
41. Ramos-Cazals M., Brito-Zeron P., Nardi N., Claver G., Risco G., Parraga F.D., et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 43 (2004) 1454-1456
42. Snyder M.J., Jacobs M.R., Grau R.G., Wilkes D.S., and Knox K.S. Resolution of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 142 (2005) 802-803
43. Humbert M., and Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 42 (2003) 191-193
44. Font J., Ramos-Cazals M., Nardi N., Brito-Zeron P., Aguilo S., and Belenguer R. One-year prospective follow-up of bosentan treatment for severe Raynaud's phenomenon associated with systemic sclerosis. Ann Rheum Dis 64 III (2005) 278
45. Watanabe H., Ohashi K., Takeuski K., Yamashita K., Yokoyama T., Ttran Q., et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71 (2002) 398-402
46. Kumana C.R., Cheung G.T.Y., and Lau C.S. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 63 (2004) 1522-1524
47. Rosenkranz S., Diet F., Karasch T., Weibrauch J., Wasserman K., and Erdman E. Sildanefil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Int Med 139 (2003) 871-873
48. Kumar N., Allen J., Murray A., and Griffiths B. A pilot study assessing the response of a single dose of sildenafil citrate in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Rheumatology 2 Suppl (2004) 97
49. Gore J., and Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64 (2005) 1387
50. Kamata Y., Kaminura T., Iwamoto M., and Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 30 (2005) 451
51. Coleiro B., Marshall S.E., Denton C.P., Howell K., Blann A., Welsch K.J., et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40 (2001) 1038-1043
52. Dziadzio M., Denton C.P., Smith R., Howell K., Blann A., Bowers E., et al. Losartan therapy for Raynaud's phenomenon and scleroderma. Arthritis Rheum 42 (1999) 2646-2655
53. Hirschi M., Katzenschlager R., Francesconi C., and Kundi M. Low level laser therapy in primary's Raynaud's phenomenon- Results of a placebo controlled double blind intervention study. J Rheumatol 31 (2004) 2408-2412
54. Matsumoto Y., Ueyama T., Endo M., Sasaki H., Kasashima F., Abe Y., et al. Endoscopic thoracic sympathicotomy for Raynaud's phenomenon. J Vasc Surg 36 (2002) 57-61
55. Kotsis S.V., and Chung K.C. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 30 (2003) 1788-1792